drugset / Trial / NCT00857467

Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

NCT00857467 ↗

Phase 1 Completed 36 enrolled Norgine
RandomizedCrossoverTriple-blindTreatment

Summary

This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A further 12 subjects will receive three single administrations of 2 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile will be determined.

Timeline

Start
2009-02
Primary completion
2009-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject NRL001 Small molecule 5 mg Other
Subject NRL001 Small molecule 10 mg Other
Subject NRL001 Small molecule 15 mg Other

Indications

No indication recorded.